Navigation Links
EntreMed Reports Second Quarter 2013 Financial Results
Date:8/14/2013

ROCKVILLE, Md., Aug. 14, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today reported financial results for the three and six-month periods ended June 30, 2013. 

(Logo:  http://photos.prnewswire.com/prnh/20010620/ENMDLOGO

EntreMed reported a net loss for the second quarter of 2013 of ($1.9 million), or ($0.07) per share. This compares with a net loss of ($10.5 million), or ($0.56) per share, for the same period last year.
For the first six months of 2013 the reported net loss was ($3.0 million), or ($0.12) per share as compared to ($13.0 million), or ($0.86) per share for 2012.  The 2012 net loss was primarily attributed to non-cash interest charges associated with our financing in 2012 ($9.2 million and $10.0 million for the three and six months ended June 30, 2012, respectively).  Excluding this non-cash interest, net loss for the second quarter and first six months of 2012 was ($1.3 million), or ($0.07) per share and ($3.0 million) or ($0.19) per share, respectively.

As of June 30, 2013, EntreMed had cash and cash equivalents of approximately $17.2 million.

Sara B. Capitelli, EntreMed's Vice President, Finance & Principal Accounting Officer, commented on the second quarter results, "Our second quarter 2013 financial results were in line with expectations.  Our research and development expenses for the second quarter increased compared to the previous year due to costs associated with the clinical development of ENMD -2076 in the U.S. and China during 2013.  Our general and administrative expenses for the second quarter of 2013 increased compared to the previous year, reflecting an increase in non-cash stock based compensation of $0.4 million.  We anticipate third and fourth quarter research and development expenses to increase primarily due to costs related to the Company's crossover bioavailability and food effect study of ENMD-2076."

Ken Ren, PhD, EntreMed's Chief Executive Officer, further commented, "Our finances are stable and reflect our prudent management of resources.  As we continue to deploy our capital in value-building and efficient ways, we continue to advance the clinical development of ENMD-2076, expand our capability in China, and will explore opportunities to enhance value and build our pipeline.  We are optimistic about our company's prospects and look forward to further execution of our drug development strategy." 

About ENMD-2076 
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, multiple myeloma, and is currently completing a Phase 2 trial for ovarian cancer.  EntreMed is currently conducting a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer and a Phase 2 study in advanced/metastatic soft tissue sarcoma. ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.

About EntreMed
EntreMed is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer.  EntreMed is currently conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer and a Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma.  The Company is headquartered in Rockville, Maryland and has a wholly-owned subsidiary in Beijing, China.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals.  Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid® resulting in reduced or no royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission ("SEC"), which are available at www.sec.gov.

COMPANY CONTACT: 
Investor Relations 
EntreMed, Inc. 
240.864.2643 
investorrelations@entremed.com

 

(Financial Table Attached) ENTREMED, INC.SUMMARY OF OPERATING RESULTS(Unaudited)Three Months Ended June 30,2013

2012Total revenues$$Costs and Expenses:  Research and development836,582

696,287General and administrative1,015,701

601,502Interest Expense (Income)(443)

9,165,429Net loss(1,851,840)

(10,463,218)Net loss per share (basic and diluted)$
(0.07)

$
(0.56)attributable to common shareholdersWeighted average number of shares outstanding27,023,038

18,979,559(basic and diluted)Six Months Ended June 30,2013

2012Total revenues$$Costs and Expenses:Research and development1,342,957

1,257,536General and administrative1,645,603

1,698,248Interest Expense (Income)(833)

10,041,292Net loss(2,987,727)

(12,997,076)Net loss per share (basic and diluted) $
(0.­­12)

$
(0.86)attributable to common shareholdersWeighted average number of shares outstanding25,200,535

15,568,841(basic and diluted)Cash and cash equivalents$17,222,918

$10,058,935 


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMed Reports First Quarter 2012 Financial Results
2. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
3. EntreMed Reports Second Quarter 2012 Financial Results
4. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
5. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
6. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
7. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
8. EntreMed To Raise $10.7 Million In Registered Direct Offering
9. EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
10. EntreMed Announces Changes to Board of Directors and CEO Appointment
11. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ® Technologies, Inc. announces that the Journal ... of Vibration on Molar Distalization," a study that focused ... Bowman , this prospective, peer-reviewed clinical study concluded that ... speeds up molar distalization rates in the apex ... to move the upper molars into a normal, Class ...
(Date:1/17/2017)... , Jan. 17, 2017 Following an ... today praised the Food and Drug Administration,s (FDA,s) ... Human Drug Products by Pharmacies and Outsourcing Facilities." ... proposed limitation on pre-packaging -- which would have ... costs to long term care (LTC) pharmacies.  ...
(Date:1/17/2017)... DUBLIN , Jan 17, 2017 Research ... Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, ... CVD) - Global Forecast to 2021" report to their offering. ... The global ... by 2021 from USD 157.95 Billion in 2016, growing at a ...
Breaking Medicine Technology:
(Date:1/17/2017)... , ... January 17, 2017 , ... Neil H. Greco ... planning assistance to communities throughout the region, is launching a charity drive to raise ... is by far the deadliest killer in America, and is responsible for 1 in ...
(Date:1/17/2017)... ... ... SC&H Group, a leading audit, tax, and consulting firm, announced that Chris Rossi ... . Rossi is the third technology consulting leader to join SC&H Group’s IT Advisory ... practice continues to expand.     , Bringing more than 25 years of business consulting and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon ... cyber threats in real-time, today announced a strategic partnership with TechLab Security, ... Joining other Seceon partners, TechLab Security has become a strategic partner and a ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... offices in Tyler, has announced the latest beneficiary of their thriving community involvement ... nonprofit organization dedicated to fulfilling the dreams of terminally ill patients. Donations to ...
(Date:1/17/2017)... ... ... Many people make New Year’s resolutions or renew their commitment to better health with the ... people who want to kick off 2017 with better smiles. Dr. Mondavi is offering several ... offers include: , , A new patient package for just $49, ...
Breaking Medicine News(10 mins):